Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,681 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S. Smyth LM, et al. Among authors: wong a. NPJ Breast Cancer. 2021 Apr 16;7(1):44. doi: 10.1038/s41523-021-00251-7. NPJ Breast Cancer. 2021. PMID: 33863913 Free PMC article.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators. Kim SB, et al. Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8. Lancet Oncol. 2017. PMID: 28800861 Free PMC article. Clinical Trial.
Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study.
Heong V, Syn NL, Lee XW, Sapari NS, Koh XQ, Adam Isa ZF, Sy Lim J, Lim D, Pang B, Thian YL, Ng LK, Wong AL, Soo RA, Yong WP, Chee CE, Lee SC, Goh BC, Soong R, Tan DSP. Heong V, et al. Int J Cancer. 2018 May 1;142(9):1890-1900. doi: 10.1002/ijc.31091. Epub 2017 Oct 17. Int J Cancer. 2018. PMID: 28994108
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer.
Yadav K, Lim J, Choo J, Ow SGW, Wong A, Lee M, Chan CW, Hartman M, Lim SE, Ngoi N, Tang SW, Ang Y, Chan G, Chong WQ, Tan HL, Tan SH, Goh BC, Lee SC. Yadav K, et al. Among authors: wong a. Breast Cancer Res Treat. 2022 Feb;192(1):131-142. doi: 10.1007/s10549-021-06470-7. Epub 2021 Dec 20. Breast Cancer Res Treat. 2022. PMID: 34928481 Free PMC article. Clinical Trial.
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.
Lim JSJ, Wong ALA, Ow SGW, Ngoi NYL, Chan GHJ, Ang YLE, Chong WQ, Lim SE, Lim YW, Lee M, Choo JRE, Tan HL, Yong WP, Soo RA, Tan DSP, Chee CE, Sundar R, Yadav K, Jain S, Wang L, Tai BC, Goh BC, Lee SC. Lim JSJ, et al. Among authors: wong ala. Clin Cancer Res. 2022 Jun 1;28(11):2248-2256. doi: 10.1158/1078-0432.CCR-21-4179. Clin Cancer Res. 2022. PMID: 35363275 Clinical Trial.
Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit.
Walsh RJ, Ong R, Cheo SW, Low PQJ, Jayagopal A, Lee M, Ngoi N, Ow SG, Wong ALA, Lim SE, Lim YW, Heong V, Sundar R, Soo RA, Chee CE, Yong WP, Goh BC, Lee SC, Tan DSP, Lim JSJ. Walsh RJ, et al. Among authors: wong ala. Front Oncol. 2024 May 15;14:1342346. doi: 10.3389/fonc.2024.1342346. eCollection 2024. Front Oncol. 2024. PMID: 38812774 Free PMC article.
7,681 results